PCR-based genotyping for duplicated and deleted CYP2D6 genes

Pharmacogenetics

Volumn 6, Issue 4, 1996, Pages 351-355

  Johansson, Inger ^a   Lundqvist, Eva ^a   Dahl, Marja Liisa ^b   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytochrome P450; Debrisoquine; Gene amplification; Gene duplication; Long PCR; Neuroleptics; Sparteine; Tricyclic antidepressants

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DNA; NEUROLEPTIC AGENT; OXYGENASE; SPARTEINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLELE; ARTICLE; DNA SEQUENCE; DRUG METABOLISM; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TECHNIQUE;

EID: 0029756509     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199608000-00008     Document Type: Article

References (12)

1. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995: 57, 265-269.
2. Bertilsson L, Dahl M-L, Sjöqvist F, Äberg-Wistedt A, Humble M, Johansson I, Lundqvist E. Ingelman-Sundberg M. Molecular basis for rational mega-prescribing in ultrarapid hydroxylators of dehrisoquine. Lancet 1993: 341, 63.
3. Bertilsson L, Dahl M-L, Ingelman-Sundberg M, Johansson I, Sjöqvist F. Interindividual and interethnic differences in polymorphic drug oxidation - implications for drug therapy with focus on psychoactive drugs. In: Pacifici G, Fracchia GN, eds Advances in drug metabolism in man, EUR 15439 EN, EC, DGXII-E-4, 1995: 85-136.
4. Cheng S, Fockler C, Barnes WM, Higuchi R. Effective amplification of long targets from cloned inserts and human genomic DNA. Proc Natl Acad Sci (USA) 1994: 91, 5695-5699.
5. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995: 274, 516-520.
6. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
7. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
8. Hengen PN. Methods and reagents - long and accurate PCR. Trends Biochem Sci 1994: 19, 341-342
9. Ingelman-Sundberg M, Johansson I. The molecular genetics of the human drug metabolizing cytochrome P450s. In: Pacific G. Fracchia eds, Advances in drug metabolism in man, EUR 15439 EN, EC, DGXII-E-4, Luxembourg: Office for official publications of the European Communities 1995: 543-586.
10. Johansson I, Yue QY, Dahl M-L, Heim M, Bertilsson L, Meyer UA, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. EurJ Clin Pharmacol 1991: 40, 553-556.
11. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P4502D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci (USA) 1993: 90, 11825-11829.
12. Steen VM, Andreassen OA, Daly AK, Tefre T, Börresen A-L, Idie J, Gulbrandsen A-K. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion by long PCR technology. Pharmacogenetics 1995, 4, 215-224.